Voyager Therapeutics, Inc. (NASDAQ:VYGR) Insider Todd Alfred Carter Sells 10,500 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 10,500 shares of Voyager Therapeutics stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $8.16, for a total value of $85,680.00. Following the completion of the transaction, the insider now owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Todd Alfred Carter also recently made the following trade(s):

• On Thursday, July 6th, Todd Alfred Carter sold 5,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.80, for a total transaction of $59,400.00.

Voyager Therapeutics Trading Up 2.4 %

Shares of NASDAQ VYGR traded up $0.19 during trading hours on Monday, reaching $8.15. The stock had a trading volume of 275,681 shares, compared to its average volume of 465,678. The firm has a 50-day moving average of $9.29 and a 200-day moving average of $9.59. The firm has a market cap of $357.79 million, a price-to-earnings ratio of 3.51 and a beta of 1.03. Voyager Therapeutics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The firm had revenue of $4.85 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, equities analysts predict that Voyager Therapeutics, Inc. will post 1.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VYGR. Oppenheimer reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Voyager Therapeutics in a report on Monday, August 7th. StockNews.com assumed coverage on shares of Voyager Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating for the company.

Institutional Trading of Voyager Therapeutics

Large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in Voyager Therapeutics in the second quarter valued at $121,000. Nuveen Asset Management LLC acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $1,012,000. Alliancebernstein L.P. purchased a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $220,000. Wells Fargo & Company MN lifted its position in Voyager Therapeutics by 624.2% during the 2nd quarter. Wells Fargo & Company MN now owns 14,962 shares of the company’s stock worth $171,000 after acquiring an additional 12,896 shares during the period. Finally, Vestcor Inc purchased a new position in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $437,000. Institutional investors and hedge funds own 58.81% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.